[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE403652T1 - Imidazolderivate und deren verwendung als peripheral-selektive inhibitoren von dopamin-beta-hydroxylasen - Google Patents

Imidazolderivate und deren verwendung als peripheral-selektive inhibitoren von dopamin-beta-hydroxylasen

Info

Publication number
ATE403652T1
ATE403652T1 AT03256420T AT03256420T ATE403652T1 AT E403652 T1 ATE403652 T1 AT E403652T1 AT 03256420 T AT03256420 T AT 03256420T AT 03256420 T AT03256420 T AT 03256420T AT E403652 T1 ATE403652 T1 AT E403652T1
Authority
AT
Austria
Prior art keywords
hydroxylases
peripheral
selective inhibitors
imidazole derivatives
dopamine beta
Prior art date
Application number
AT03256420T
Other languages
English (en)
Inventor
David Alexander Learmonth
Da Silva Patricio Manue Soares
Alexander Beliaev
Original Assignee
Bial Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial Portela & Ca Sa filed Critical Bial Portela & Ca Sa
Application granted granted Critical
Publication of ATE403652T1 publication Critical patent/ATE403652T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03256420T 2002-10-11 2003-10-10 Imidazolderivate und deren verwendung als peripheral-selektive inhibitoren von dopamin-beta-hydroxylasen ATE403652T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0223719A GB2393958A (en) 2002-10-11 2002-10-11 Peripherally-selective imidazole inhibitors of dopamine-beta-hydroxylase
GB0224306A GB2394223B (en) 2002-10-11 2002-10-18 Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation

Publications (1)

Publication Number Publication Date
ATE403652T1 true ATE403652T1 (de) 2008-08-15

Family

ID=9945777

Family Applications (5)

Application Number Title Priority Date Filing Date
AT03256420T ATE403652T1 (de) 2002-10-11 2003-10-10 Imidazolderivate und deren verwendung als peripheral-selektive inhibitoren von dopamin-beta-hydroxylasen
AT07076125T ATE505465T1 (de) 2002-10-11 2003-10-10 Chroman- und thiochroman-3-yl-1,3- dihydroimidazole als hemmer der dopamin-beta- hydroxylase und verfahren zu ihrer herstellung
AT07076122T ATE500248T1 (de) 2002-10-11 2003-10-10 Silyl-geschützte hydroxymethyl-carbamoylalkyl- ketone als intermediate in der herstellung von dopamine-beta-hydroxylase inhibitoren
AT07076123T ATE550335T1 (de) 2002-10-11 2003-10-10 3,4-dihydro-3-amino-2h-1-benzopyran und - benzothiopyran derivate als dopamine-beta- hydroxylase inhibitoren und verfahren zu ihrer herstellung
AT07076124T ATE500247T1 (de) 2002-10-11 2003-10-10 Verfahren zur herstellung von 3-(1,3- dihydroimidazol-2-thion-1-yl)-chromanen und thiochromanen als dopamin-beta-hydroxylase inhibitor

Family Applications After (4)

Application Number Title Priority Date Filing Date
AT07076125T ATE505465T1 (de) 2002-10-11 2003-10-10 Chroman- und thiochroman-3-yl-1,3- dihydroimidazole als hemmer der dopamin-beta- hydroxylase und verfahren zu ihrer herstellung
AT07076122T ATE500248T1 (de) 2002-10-11 2003-10-10 Silyl-geschützte hydroxymethyl-carbamoylalkyl- ketone als intermediate in der herstellung von dopamine-beta-hydroxylase inhibitoren
AT07076123T ATE550335T1 (de) 2002-10-11 2003-10-10 3,4-dihydro-3-amino-2h-1-benzopyran und - benzothiopyran derivate als dopamine-beta- hydroxylase inhibitoren und verfahren zu ihrer herstellung
AT07076124T ATE500247T1 (de) 2002-10-11 2003-10-10 Verfahren zur herstellung von 3-(1,3- dihydroimidazol-2-thion-1-yl)-chromanen und thiochromanen als dopamin-beta-hydroxylase inhibitor

Country Status (11)

Country Link
KR (1) KR101350741B1 (de)
CN (1) CN100393715C (de)
AR (2) AR041589A1 (de)
AT (5) ATE403652T1 (de)
CY (2) CY1108452T1 (de)
DE (4) DE60336276D1 (de)
DK (2) DK1408038T3 (de)
ES (5) ES2361939T3 (de)
GB (2) GB2393958A (de)
HK (1) HK1116188A1 (de)
SI (2) SI1408038T1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0708818D0 (en) * 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
KR101941467B1 (ko) * 2010-12-22 2019-01-23 바이알 - 포르텔라 앤드 씨에이 에스에이 결정형 및 이들의 제조방법
GB201316410D0 (en) 2013-09-13 2013-10-30 Bial Portela & Ca Sa Processes for preparing peripherally-selective inhibitors of dopamine-?-hydroxylase and intermediates for use therein

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL82401A0 (en) * 1986-05-06 1987-11-30 Merrell Dow Pharma Dopamine beta hydroxy-lase inhibiting imidazole derivatives and pharmaceutical compositions containing them
US4868210A (en) 1988-03-30 1989-09-19 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic compounds and compositions
ATE243199T1 (de) * 1994-04-26 2003-07-15 Syntex Llc Benzocyclohexylimidazolthion-derivate

Also Published As

Publication number Publication date
DE60336772D1 (de) 2011-05-26
SI1908760T1 (sl) 2011-05-31
CY1108452T1 (el) 2014-04-09
ES2361939T3 (es) 2011-06-24
DE60322642D1 (de) 2008-09-18
CY1112457T1 (el) 2015-12-09
ES2309279T3 (es) 2008-12-16
SI1408038T1 (sl) 2008-10-31
ATE500247T1 (de) 2011-03-15
DK1908760T3 (da) 2011-07-25
HK1116188A1 (en) 2008-12-19
GB2394223B (en) 2007-05-16
CN1726211A (zh) 2006-01-25
GB0224306D0 (en) 2002-11-27
GB2394223A (en) 2004-04-21
GB2393958A (en) 2004-04-14
ATE550335T1 (de) 2012-04-15
DK1408038T3 (da) 2008-11-24
KR20120038014A (ko) 2012-04-20
CN100393715C (zh) 2008-06-11
ES2364919T3 (es) 2011-09-16
ES2384118T3 (es) 2012-06-29
ATE505465T1 (de) 2011-04-15
AR041589A1 (es) 2005-05-26
DE60336276D1 (de) 2011-04-14
ATE500248T1 (de) 2011-03-15
KR101350741B1 (ko) 2014-01-10
DE60336275D1 (de) 2011-04-14
ES2361938T3 (es) 2011-06-24
AR095674A2 (es) 2015-11-04
GB0223719D0 (en) 2002-11-20

Similar Documents

Publication Publication Date Title
DE60332023D1 (de) Chinolinderivate und deren verwendung als mycobakterielle inhibitoren
ATE419849T1 (de) Diaminotriazole derivate und deren verwendung als protein kinase inhibitoren
DE602004021037D1 (de) Phosphororganische indazolderivate und deren verwendung als proteinkinaseinhibitoren
ATE420861T1 (de) 2-pyridonderivate als inhibitoren von neutrophilelastase und deren verwendung
DE60133897D1 (de) Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
ATE447404T1 (de) Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
DE60308387D1 (de) Pyrazolenthaltende zusammensetzungen und ihre verwendung als gsk-3 inhibitoren
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
DE60234167D1 (de) Bipiperidin-derivate und ihre verwendung als inhibitoren der chemokinrezeptoren
DE60030574D1 (de) Fünfgliedrige derivate von heterozyklen und ihre verwendung als monoaminoxidase-inhibitoren
DE60221233D1 (de) Neue spirotricyclische derivate und deren verwendung als phosphodiesterase-7-inhibitoren
ATE443048T1 (de) 4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren
DE60309342D1 (de) Benzimidazole und benzothiazole als inhibitoren der map-kinase
ATE449605T1 (de) N3-alkylierte benzimidazol-derivate als mek- hemmer
DE602005015699D1 (de) Prolinderivate und deren verwendung als dipeptidylpeptidase-iv-inhibitoren
DE60324166D1 (de) Dihydropyridinderivaten zur verwendung als inhibitoren der menschlichen neutrophilenelastase
ATE472546T1 (de) 5-heteroarylthiazole und deren verwendung als pi3k-inhibitoren
ATE431346T1 (de) Substituierte naphthylindolderivate und ihre verwendung als plasminogen aktivator inhibitor (pai-1) inhibitoren
DE50311397D1 (de) Heterocyclisch substituierte indolinone und deren verwendung als rezeptor-tyrosinkinasen inhibitoren
DE602005025110D1 (de) Heterocyclische verbindungen und deren verwendung als aldosteronsynthaseinhibitoren
ATE399768T1 (de) Indazolderivate und ihre verwendung als crf antagonisten
DE50313157D1 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
ATE551329T1 (de) Chinazolinonderivate und deren verwendung als cb- agonisten
ATE500242T1 (de) Substituierte 1-piperidin-4-yl-pyrrolidin-3-yl- piperazinderivate und deren verwendung als neurokinin antagonisten
ATE382040T1 (de) Acylaminothiazolderivate und ihre vewrendung als beta-amyloid inhibitoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1408038

Country of ref document: EP